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September 2011, and with Carbon ion beam in 2012. 
Skullbase chordomas are known as radioresistant tumors. 
Escalating the dose to target volumes and sparing normal 
organs is recommended to ensure adequate local control with 
low toxicity.  
Materials and Methods: Since September 2011, 67 patients ( 
F/M : 25/42) with histologically verified diagnosis of skullbase 
chordomas have been treated at CNAO. All patients 
underwent first one or more surgical procedures, and then 
were irradiated on macroscopic residual disease or on the 
site of local relapse ( 2 patients had local relapse after 
complete resection). Thirty nine patients have been treated 
with proton beam, up to a total dose of 74 GyE in 37 
fractions, 2 GyE/fraction over 5 days per week, twenty eight 
patients with carbon ion up to70.4 GyE in 16 fractions, 4.4 
GyE/fraction over 4 days per week. Each patient underwent 
clinical examination during, at the end and every three 
months after the treatment. Acute and late toxicity data 
were recorded according to CTCAE v.4.0 score. Clinical 
outcome was evaluated with trimestral MRI according to 
RECIST criteria. 
Results: Treatment has been in general well tolerated, with 
acute toxicity G0/G1, G2 and G3 reported respectively in 
74%, 24% and 2% patients; one patient died for causes not 
treatment related. 
With 15 months median follow up time ( range 2 – 27), local 
control was achieved in 51 patients (over the 54 who reached 
the first follow up visit), partial response in 2, and complete 
response in 1. No progression disease has been reported. In 
the 34 patients who reached 12 months follow up, 26 patients 
were scored with late toxicity G0/G1 (alopecia, fatigue, 
dysphagia, headache, hearing loss), and 8 patients with G2 
(pituitary deficit, neuropathy, asymptomatic brain 
dysfuncion). 
Conclusions: Our data show safety and effectiveness of 
handrontherapy for skullbase chordomas although the limited 
number of patients and the short follow up time. Longer 
follow up are needed. 
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Purpose/Objective: In brain 1H Magnetic Resonance 
Spectroscopic Imaging (MRSI) elevated choline and reduced 
NAcetylAspartate (NAA) levels are both indicators of 
cancerous tissue and the Choline/NAA Ratio (CNR) is a widely 
studied parameter for evaluating tumor metabolic function. 
In this study we compare CNRs in healthy tissue and tumor 
across a cohort of GlioBlastoma Multiforme (GBM) patients 
and investigate the link between spectroscopic abnormality 
and disease-free survival after treatment. 
Materials and Methods: 14 patients diagnosed with GBM 
underwent an MRSI exam as part of the (post-operative) 
radiotherapy treatment planning imaging process. The scan 
was a PRESS localized CSI with 10x10x8 voxels of 
approximately 0.5cc, TE/TR=135ms/1.5s. Data was 
processed, quantified, registered to the coacquired T1 
contrast enhanced scan and resampled to the T1 resolution 
using a custom tool developed in-house. After treatment, 
every patient received follow up MRIs every 1-2 months until 
relapse. 
Amongst GBM patients a GTV to CTV margin of 20mm is 
typically used to account for microscopic spread. Voxels 
greater than 20mm outside the CTV contour were classified 
as 'normal' and for each patient a Gaussian distribution was 
fitted to the CNRs of these voxels to obtain a mean normal 
CNR. As the CNRs in the contrast enhanced region do not 
typically form a Gaussian distribution, the median value was 
utilised. The Choline/NAA Enhancement (CNE) was defined as 
the ratio between median tumour CNR and mean normal 
CNR. 
Results: The normal tissue CNR across the group was 0.84 +/- 
0.10, showing a wide range of healthy tissue values across 
patients. Four patients exhibited no voxels with 
spectroscopic abnormalities. The mean CNE was 1.73 +/- 
0.65. 
Patients were divided into two groups (equal in number) 
based on the mean CNE and disease-free survival curves for 
both were constructed using the Kaplan-Meier estimator, 
shown in the figure, then compared using the log rank test, 
which showed a significant difference (p=0.00645) between 
the two groups.  
 
 
Conclusions: Our study found the baseline levels of 
metabolites to vary substantially between patients 
(attributable at least in part to tumor location), so that an 
absolute threshold for abnormal CNR cannot be determined 
for all patients. Instead we proposed a measure of relative 
abnormality, CNE, which can be compared across patients. 
There is a statistically significant relationship between our 
CNE and the disease-free survival of our patient cohort. Thus 
this study demonstrates that spectroscopic analysis of the 
CNE could help guide treatment planning by indicating 
patients who might benefit from more radical radiotherapy 
options such as dose boosting. The metric could also be used 
to tailor patient follow-up in order to more closely monitor 
patients with high risk of early relapse. 
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Purpose/Objective: Prognosis in recurrent glioblastoma is 
very poor with survival of 3-6 months. Bevacizumab,a 
humanized VEGF monoclonal antibody, exhibits evidence of 
apparent antitumor benefit, although these data remain 
controversial. We analyze a group of sequential patients in 
which Bevacizumab was used as off-label drug combined with 
chemotherapy and low dose radiation therapy (LDRT). 
The aim is to evaluate feasibility, tolerance and response. 
Materials and Methods: We enrolled patients (KPS > 70,age 
>18 years) with recurrent GBM after Temozolomide. 
Bevacizumab (10 mg/m2 every 14 days) was administered 
alone or in combination with Fotemustine (100 mg/m2 2nd day 
every 14 days) or Irinotecan (125 mg/m2 every 14 days) 
Lomustine (110 mg/m2 every 6 weeks). 
LDRT (0.60 Gy twice daily) was administrated at least 4 hours 
apart, for 2 days every 14 days; 5 cycles were planned. 
Clinical Target Volume included the tumor with surgical 
cavity, plus a 30-mm margin.  
Toxicity was evaluated according to the Common 
Terminology Criteria for Adverse Events version 4.0; response 
was based on RECIST Guidelines; the overall survival (OS) and 
the progression-free survival (PFS) was calculated by the 
Kaplan-Mayer method. 
Results: We enrolled 34 patients from July 2011 to February 
2014; median age at the time of recurrence was 52 years 
(range 22-77) with a median time to recurrence of 11.76 
months ( range 3.25-102.6).  
Twentyfive out of 34 pts (73.5 %) received Bevacizumab plus 
Fotemustine, 3/34 (8.8%) Bevacizumab with Irinotecan, 3/34 
(8.8%) Bevacizumab with Lomustine and 2/34 (5.8%) 
Bevacizumab alone, instead 15/34(44%) received LDRT. 
Median dose of LD-RT was 960 cGy (range 480-2400 cGy).  
Bevacizumab was prescribed in14/34 at the first relapse, in 
15/34 (44%) at the second progression and in 5/34 (14.7%) at 
the third one. 
Grade 1-2 of leukopenia and/or thrombocytopenia were 
recorded in 6/34 pts (17.6%), and G3-4 in 8/34pts (23.5%). In 
one case we observed a cerebral haemorrhage. After 5 cicles 
we observed 2 complete response (5.8%), 5 partial responses 
(14.7%), 5 stable diseases (14.7%), and 17 progression 
diseases (50%). 
With a median follow up from recurrence of 41 months (range 
16-130), 7 patients(20.6%) are alive with disease and 27 are 
died(79.4%). Median OS and PFS from first progression were 
26,4 and 11,76 months respectively. 
No statistically differences was observed in OS (p= 0.97) and 
PFS ( p= 0.16) with or without LDRT. 
Conclusions: Bevacizumab in combination with LD-RT and 
chemotherapy is feasible and quite well tolerated; but 
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Purpose/Objective: The optimal treatment approach for 
recurrent glioblastoma multiforme (rGBM) in elderly and/or 
frail patients (pts) remains virtually unexplored and the best 
supportive care (BSC) only is often considered appropriate 
due to the very poor prognosis. The aim of this study was to 
evaluate the impact of different treatment methods on post-
progression survival (PPS) and overall survival (OS) of such 
pts. 
Materials and Methods: We performed a retrospective 
analysis of the data from 100 pts treated between 2010 and 
2013 within the phase III IAEA study NCT1450449 which 
compared one-week with a standard three-week radiotherapy 
(RT) regimen in elderly and/or frail pts with GBM (Frail: ≥50 
years, KPS 50 – 70; Elderly and frail: ≥65 years, KPS 50 – 70; 
Elderly: ≥65 years, KPS 80 – 100). Date and site of relapse, 
KPS at relapse and treatment of relapse – surgery, RT, 
chemotherapy (CHT) or BSC only, were recorded. Kaplan-
Meier method was used to estimate PPS and OS rates for 
different treatment modalities; subgroups were compared 
with the log-rank test. 
Results: Eighty-four out of 100 pts (41 after one-week RT; 43 
after three-week RT) enrolled in the study experienced a 
relapse. At progression, 47 pts (56%) received BSC only, 21 
(25%) received CHT, 8 (9.5%) received surgery (two of them: 
surgery + CHT, one: surgery + RT), three pts (3.5%) received 
RT, for 5 (6%) pts no such data was available. Median 
progression free survival from randomization was 16 weeks, 
15 weeks for the group of pts who received any treatment of 
recurrence and 16 weeks for the group with BSC (p = 0.89). 
Baseline characteristics were similar in the two groups, 
except for the extent of the primary surgery – all pts who 
received any treatment of recurrence had undergone primary 
total (35%) or subtotal (65%) resection, whereas in the group 
with BSC 25% had had biopsy only, 61% had subtotal and 17% 
had total resection, p = 0.01. After a median post progression 
follow-up of 13 weeks (range: 0 – 78), 74 pts (88%) have died, 
median PPS was 15 weeks. Median PPS for pts who received 
